OverviewSuggest Edit

Arcus Biosciences is a biotech company that visions to create new cancer therapeutics through the use of emerging insights in immunology. The Company's lead program targets the adenosine pathway, which has been shown to play a significant role in driving immuno-suppression in the tumor micro-environment. Like IDO inhibitors, adenosine receptor antagonists and inhibitors of adenosine production are expected to be highly synergistic with other immuno-oncology mechanisms, as well as with chemotherapy. Because of the promise of the adenosine pathway, several adenosine receptor antagonists that were discovered years ago and initially developed for other indications have been repurposed for oncology.

Arcus has generated novel, small- molecule dual antagonists of key adenosine receptors A2aR and A2bR. The Company believes that its lead molecule, AB928, will be the first clinical compound that was designed specifically for its immune-stimulating properties.  Arcus has other product candidates in earlier stages of development that target the adenosine pathway, including a CD73 inhibitor (which blocks the generation of extracellular adenosine in tumors) that could be the first small-molecule inhibitor of CD73 to enter clinical trials.

TypePublic
Founded2015
HQHayward, US
Websitearcusbio.com

Latest Updates

Employees (est.) (Feb 2019)83
Job Openings21
Revenue (FY, 2017)$1.4 M
Share Price (Jun 2020)$22.8 (-6%)
Cybersecurity ratingBMore

Key People/Management at Arcus Biosciences

Juan Jaen

Juan Jaen

President
Terry Rosen

Terry Rosen

CEO
William J. Grossman

William J. Grossman

CMO
Lixia Jin

Lixia Jin

VP, Discovery & Clinical DMPK
Jason Barker

Jason Barker

VP, Finance and Principal Financial Officer
Katherine Bock

Katherine Bock

VP, Investor Relations and Corporate Strategy
Show more

Arcus Biosciences Office Locations

Arcus Biosciences has an office in Hayward
Hayward, US (HQ)
3928 Point Eden Way
Show all (1)

Arcus Biosciences Financials and Metrics

Arcus Biosciences Revenue

Arcus Biosciences's revenue was reported to be $1.41 m in FY, 2017
USD

Revenue (FY, 2017)

1.4m

Net income (FY, 2017)

(53.1m)

EBIT (FY, 2017)

(53.4m)

Market capitalization (26-Jun-2020)

1.0b

Closing stock price (26-Jun-2020)

22.8

Cash (31-Dec-2017)

98.4m
Arcus Biosciences's current market capitalization is $1 b.
USDFY, 2016FY, 2017

Revenue

1.4m

General and administrative expense

3.9m7.6m

R&D expense

14.2m47.2m

Operating expense total

18.2m54.9m
USDFY, 2016FY, 2017

Cash

65.2m98.4m

Prepaid Expenses

390.0k1.1m

Current Assets

99.7m176.9m

PP&E

8.6m11.2m
USDFY, 2016FY, 2017

Net Income

(18.0m)(53.1m)

Depreciation and Amortization

1.3m2.6m

Accounts Payable

3.6m(267.0k)

Cash From Operating Activities

(12.9m)(25.1m)
USDFY, 2016

Financial Leverage

1.1 x
Show all financial metrics

Arcus Biosciences Cybersecurity Score

Cybersecurity ratingPremium dataset

B

84/100

SecurityScorecard logo

Arcus Biosciences Online and Social Media Presence

Embed Graph

Arcus Biosciences News and Updates

BRIEF-James Tananbaum Reports 9.6 PCT Passive Stake In Arcus Biosciences Inc As Of March 14

* JAMES TANANBAUM REPORTS 9.6 PERCENT PASSIVE STAKE IN ARCUS BIOSCIENCES INC AS OF MARCH 14, 2018 - SEC FILING‍​ Source text - https://bit.ly/2pEVSbN Further company coverage:

Arcus Biosciences Blogs

Arcus Biosciences Announces FDA Clearance of INDs for AB928 and AB122 and Initiation of Phase 1/1b Program to Evaluate AB928 Combinations

The post Arcus Biosciences Announces FDA Clearance of INDs for AB928 and AB122 and Initiation of Phase 1/1b Program to Evaluate AB928 Combinations appeared first on Arcus Biosciences.

Arcus Biosciences Announces FDA Clearance of INDs for AB928 and AB122 and Initiation of Phase 1/1b Program to Evaluate AB928 Combinations

The post Arcus Biosciences Announces FDA Clearance of INDs for AB928 and AB122 and Initiation of Phase 1/1b Program to Evaluate AB928 Combinations appeared first on Arcus Biosciences.

Arcus Biosciences Announces Participation at Upcoming Investor Conference

The post Arcus Biosciences Announces Participation at Upcoming Investor Conference appeared first on Arcus Biosciences.
Show more

Arcus Biosciences Frequently Asked Questions

  • When was Arcus Biosciences founded?

    Arcus Biosciences was founded in 2015.

  • Who are Arcus Biosciences key executives?

    Arcus Biosciences's key executives are Juan Jaen, Terry Rosen and William J. Grossman.

  • How many employees does Arcus Biosciences have?

    Arcus Biosciences has 83 employees.

  • What is Arcus Biosciences revenue?

    Latest Arcus Biosciences annual revenue is $1.4 m.

  • What is Arcus Biosciences revenue per employee?

    Latest Arcus Biosciences revenue per employee is $17 k.

  • Who are Arcus Biosciences competitors?

    Competitors of Arcus Biosciences include Mirati Therapeutics, Merrimack Pharmaceuticals and CytomX Therapeutics.

  • Where is Arcus Biosciences headquarters?

    Arcus Biosciences headquarters is located at 3928 Point Eden Way, Hayward.

  • Where are Arcus Biosciences offices?

    Arcus Biosciences has an office in Hayward.

  • How many offices does Arcus Biosciences have?

    Arcus Biosciences has 1 office.